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Abstract
Background: The unregulated use of antibiotics not only in clinical practice but also in farm animals breeding is
causing a unprecedented growth of antibiotic resistant bacterial strains. This problem can be analyzed at different
levels, from the antibiotic resistance spreading dynamics at the host population level down to the molecular
mechanisms at the bacteria level. In fact, antibiotic administration policies and practices affect the societal system
where individuals developing resistance interact with each other and with the environment. Each individual can be
seen as a meta-organism together with its associated microbiota, which proves to have a prominent role in the
resistance spreading dynamics. Eventually, in each microbiota, bacterial population dynamics and vertical or
horizontal gene transfer events activate cellular and molecular mechanisms for resistance spreading that can also be
possible targets for its prevention.
Results: In this work we show how to use the Nets-Within-Nets formalism to model the dynamics between different
antibiotic administration protocols and antibiotic resistance, both at the individuals population and at the single
microbiota level. Three application examples are presented to show the flexibility of this approach in integrating
heterogeneous information in the same model, a fundamental property when creating computational models
complex biological systems. Simulations allow to explicitly take into account timing and stochastic events.
Conclusions: This work demonstrates how the NWN formalism can be used to efficiently model antibiotic resistance
population dynamics at different levels of detail. The proposed modeling approach not only provides a valuable tool
for investigating causal, quantitative relations between different events and mechanisms, but can be also used as a
valid support for decision making processes and protocol development.
Keywords: Antibiotic resistance, Human microbiota, Hybrid models, Computational systems biology, Petri Nets,
Nets-Within-Nets
Background
Humans, like other multicellular organisms, can be con-
sidered as meta-organisms composed of a host and
its symbiotic commensal microbiota adapted to the
niches the host provides as living environment. The
human microbiota, i.e., the microbial taxa associated with
humans, has an estimated population of a hundred tril-
lion bacterial symbionts, which outnumber the host cells
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by at least a factor of ten, and express at least ten foldmore
unique genes than their host’s genome [1]. The catalog
of these organisms and their genes represents the human
microbiome [2, 3]. Each microbiota corresponds to differ-
ent coexistent species, which altogether live in a symbiotic
relationship with the human body: microorganisms obtain
to live in a favorable niche, while the host gets differ-
ent sorts of advantages [4]. In the frame of a symbiotic
relationship with the host, bacteria and other organisms
composing the microbiota normally do not express viru-
lent traits. Indeed, one of their functions is to protect the
host from pathogens [5].
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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These complex communities of microbes that include
bacteria, fungi, viruses and other microbial and eukary-
otic species, provide a tremendous enzymatic capability
and play a fundamental role in controlling several aspects
of the host’s physiology. For example, the gut microbiome,
which is by far the most extensively studied, largely con-
tributes to processing nutrients in the gastrointestinal
tract, affecting in a significant way the composition of
what the body actually absorbs from the nutrients in tran-
sit [6]. Different gut microbiomes can extract different
amounts of energy from the same nutrients, as shown in
[7]. Over the past few years, the field of immunology has
been revolutionized by the growing understanding of how
the microbiota is able to affect the induction and educa-
tion of the mammalian immune system [8]. This trend in
the research is supported by a steadily increasing number
of launched worldwide projects on the topic [9, 10].
Different bacterial species are present in different quan-
tities depending on the specific microbiota. This depends
on how much their growth dynamics, which are con-
strained by the overall availability of resources, let them
conquer the ecological space [11]. The more space a bac-
terial species takes, the more its genetic set affects the
overall functional set of the microbiota. But the dynamic
functional profile of a microbiota takes shape after other
factors as well.
Healthy microbiotas share two common features: (i) a
uniform, trans-species core of functionalities in the corre-
sponding microbiomes, and (ii) a great diversity in terms
of species composition. This provides on one side a set
of guaranteed core functionalities and, on the other side,
a great capability for plasticity [2]. The microbiota can
recruit new functionalities in two ways:
1 new species can join the population bringing in their
different functional sets and then enlarging the
functional capabilities of the pre-existing microbiota
[12];
2 microbic cells can activate different Horizontal Gene
Transfer (HGT) mechanisms, causing the acquisition
of new functional capabilities [13]. The most studied
HGT mechanism with respect to the spreading of
antibiotic resistance is the exchange of plasmids
between bacterial cells from the same or from
different species [14].
In this work, we show how to model antibiotic resis-
tance among bacterial cells living in human microbiotas.
Such phenomenon proves to be promoted by the admin-
istration of drugs originally intended to prevent or cure
infections caused by pathogenic microbes. Antimicrobials
are a class of drugs targeting pathogenic traits in diverse
microbial species, ranging from viruses to parasites, while
antibiotics target more specifically bacterial species as
pathogens. Both classes of drugs can cause insurgence and
spread of resistance in all the bacterial populations they
come in contact with.
Since most antibiotics tend to target bacteria through
very conserved biological features [15], most of the times
they hit a large spectrum of different bacterial species at
the same time. After antibiotic administration, many bac-
terial cells (besides the pathogenic species the aggression
was directed onto) perish. Only those expressing antibi-
otic resistance towards that antibiotic survive. The death
of non-resistant bacterial populations frees a large por-
tion of the ecological space: resistant bacteria have way
less competition for resources, and thus a great advan-
tage in colonizing the niche [16]. When colonizing new
ecosystems, HGT plays a central role in the acquisition of
new capabilities, antibiotic resistance included. The dif-
ferent HGT mechanisms involve diverse genetic material,
corresponding to a wide range of different functionalities.
Most times, plasmid-mediated HGT mechanisms prove
to be the most relevant for the spread of antimicrobial
and antibiotic resistance within a microbiota [17]. Such
events are part of the physiology of interactions among
bacterial cells, providing a substrate for the microbiota’s
plasticity and adaptability to a changing environment.
Among the functionalities that bacterial cells can trans-
fer through HGT, the acquisition of antibiotic resistance
is a good example of adaptation to an hostile environ-
ment: antibiotic treatment is an environmental threat to
them, and resistance provides an evolutionary advantage.
Exchanges of genetic information through colonization by
new species or HGT mechanisms can take place not only
within a microbiota, but between different microbiotas as
well, thanks to the contacts its host has with the envi-
ronment and other hosts. Still, the dynamics underling
the spread are complex, and involve mechanisms related
to the bacterial cells and populations, as well as to the
host organisms, and their contacts with the environment,
including the different types of antibiotic administration
protocols that can be implemented.
Antibiotic resistance is therefore not only a problem of
the individual host, but it rather affects the overall system
in which the hosts live. The spread of antibiotic resistance
can definitely be framed in terms of imminent risk for
the society, for the production system, as well as for the
environment in general [18].
In this work, we introduce a computational tool to
investigate how different antibiotic protocols can affect
the spread of antibiotic resistance at different levels: from
health care management of antibiotic treatment policies
and practices, to individual patients as meta-organisms
carrying peculiar and evolving microbiotas. In other
words, we tackle this problem under a systems biology
perspective, creating a computational model that properly
integrates and manages information from the different
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system levels of interest. This work extends the preliminary
results previously published in [19] by the same authors.
The proposed model is based on Nets-Within-Nets
(NWN), a high-level Petri Nets formalism supporting the
development of multi-level and hybrid models suitable for
stochastic and timed dynamic simulations [20, 21].
NWN models are powerful tools to represent hierar-
chy and encapsulation of a system, two important char-
acteristics of the biological complexity. Moreover, they
support the use of different degrees of abstraction for dif-
ferent parts of the same model. In fact, when modeling a
multi-level biological system, the availability of informa-
tion is often not uniform for all portions of the system,
or information about different system elements or levels
is specified under different formalisms, each one having
different ways of extracting information from data. Also,
as a modeling strategy, the modeler could choose to use
the formalism differently for different parts of the model.
This can be done with the aim of finding a good trade-
off between complexity of the model and accuracy of the
representation.
In general, intended in these ways, the flexibility of the
NWN formalism allows to integrate into a single consis-
tent model several heterogeneous information, enabling
to derive simulation outcomes and predictions out of a
wide part of the biological complexity intrinsic to the sys-
tem [20]. In some cases, this can result in higher accuracy
compared to models addressing a single system level.
All these characteristics make NWN models a good
option to build decision support tools for the simulation
and analysis of antibiotic resistance spreading in selected
contexts. The possibility of simulating the evolution of
the whole system based on different starting conditions
and external stimuli is a powerful tool to support the
design, optimization and testing of innovative therapeutic
protocols and for policy making in the health care context.
Methods
This section overviews the proposed computational
model, which is able to simulate how different antibiotic
protocols can affect antibiotic resistance at the microbiota
level. After introducing the NWN formalism and moti-
vating its use for our modeling goals, a set of use cases is
described, introducing the related experimental designs.
The capabilities of the proposed modeling approach must be
consideredboth as a tool to produce new insights on biolog-
ical systems interested by the spread antibiotic resistance,
and as a tool for supporting decision making processes.
Nets-Within-Nets
Our modeling strategy is based on the Nets-Within-Nets
formalism, a high-level Petri Nets formalism supporting
multi-level and hybrid model specifications as well as
stochastic dynamic simulations [22].
In order to better explain the advantages provided by the
NWN when modeling biological systems, we start with a
brief recapitulation of the basic concepts and definitions
behind the Petri Nets formalism, and its incrementally
complex extensions.
As reviewed in [23], low-level Petri Nets are a valu-
able state-of-the-art tool for computational biology. They
combine usability and simplicity in model design with the
capability of supporting dynamic simulations and formal,
quantitative analysis. Petri Nets at their core are bipartite
graphs with two kinds of nodes: places and transitions.
Each place can contain a number of tokens, which are also
elements of the formalism providing a quantitative and
discrete representation of resources. Each transition has
rules regulating its enabling and activation. Directed arcs
link places and transitions to form the desired network
architectures. This supports the modeling and simulation
of distributed systems and processes running in parallel
and competing for resources (i.e., tokens), a typical char-
acteristic of several biological system. More specifically,
low-level Petri Nets suit the modeling requirements of
biological processes considering a single organizational
system level, and a single or few types of resources. For
example, Petri Nets can be exploited to model a metabolic
network. Places can be used to represent the molecu-
lar species involved in relevant biochemical reactions and
the enzymes carrying out that reactions. Tokens can be
used to represent discrete quantities of such biomolecules.
Eventually, transitions can be used to model the stoichio-
metric rules and kinetics of reactions.
The modeling capabilities of low-level Petri Nets are
limited when trying to account in a quantitative and holis-
tic way for the biological complexity of larger and more
complex systems. High-level formalisms extend low-level
Petri Nets, making it possible to represent more of the
system’s complexity. For example, in Colored Petri Nets
each token can carry structured information, allowing to
model different types of resources. Stochastic Petri Nets
support stochastic behaviors in simulations, while Timed
Petri Nets allow for the setting of specific timings for tran-
sition activations. Among other high-level formalisms, the
NWN formalism provides the capability of expressing a
fundamental feature of biological systems: the hierarchi-
cal organization of multiple system levels encompassing
a range of time and space scales [24]. Moreover, a NWN
follows an object-oriented paradigm expressing encapsu-
lation and selective communication, making it possible
to suitably represent biological compartmentalization and
semi-permeability of biological membranes. To allow a
hierarchical organization, tokens under the NWN for-
malism can be specified and simulated using the same
NWN formalism [22] and are therefore called net-tokens.
They are therefore instances of other NWN models,
living within and being simulated concurrently with a
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higher-level network instance. In addition to such nested
architectures, NWNmodels may include extensions from
other high-level formalisms, such as stochastic rules, col-
ored tokens and timings. In particular, the capability of
managing colored tokens, coupled with the hierarchical
organization makes it easy to handle in a consistent way
different information structures in the same model. This
is a valuable tool when building complex biological mod-
els since different organizational levels of the model may
have different ways of extracting data from experiments
and information form data (interested readers may refer
to [21] for a thorough analysis of these aspects).
In our opinion, for all these reasons, NWNmodels fulfill
the modeling requirements posed by complex biological
systems and by the diverse contributors to the the relative
knowledge generation process. This holds for the prob-
lem considered in this paper, where different system parts
evolve in a mostly independent way, at different organiza-
tional levels, exchanging information in a highly regulated
and selective way.
For model design and simulation we rely on Renew,
an integrated tool supporting the design and simulation
of high-level Petri Nets [25]. Renew follows the object-
oriented programming paradigm in which net-tokens are
instances of net classes encapsulated into higher level
nets. Renew is based on Java: each net is in fact a Java class
that can in turn be interfaced with any other class and
standard library, thus enabling to tailor the models to the
specific design needs [25]. For the sake of completeness all
models presented in this paper are reported using the full
Renew syntax, thus allowing readers to easily reproduce
the model in their computational environments. To help
readers to familiarize with this syntax, annotation through
colors and labels has been used in the figures to highlight
the high-level concepts of the proposed models.
Model construction
The main goal of this paper is to show how the NWN
formalism can be used to address the question of how
antibiotic treatment protocol design and strategies relate
to the insurgence, spread and severity of antibiotic resis-
tance within both individual humanmicrobiotas and pop-
ulations of human hosts [12].
To demonstrate the NWN flexibility and performances,
we start from the presentation of an abstract model (here-
inafter referred to asGeneral model) introducing the most
important actors involved in antibiotic resistance and
their main interactions. Being abstract, this model is ana-
lyzed resorting to generic parameters that do not have a
direct relation with a specific biological setup but recapit-
ulate the antibiotic resistance mechanism at a qualitative
level [26]. To show the proposed model at work, the sec-
ond model customizes the general framework to analyze
the specific case of antibiotic resistance in the mouse gut
microbiota considering the contribution of bacterial pre-
dation mechanisms involving Acinetobacterium and E.
Coli bacterial cells [27, 28]. In this specific case, realistic
parameters (e.g., bacterial populations size, HGT rate, etc.)
are identified from the literature and plugged into the
proposed model as will be described in the following
sections.
In both cases the goal of the proposed model is to sim-
ulate and observe to what extent mild or severe resistance
spread within a single microbiota and in a population of
hosts. This is evaluated comparing: (1) a control popula-
tion not receiving any treatment, (2) a population receiv-
ing traditional antibiotic treatment, and (3) a population
receiving antibiotics under a carefully designed innovative
administration protocol.
Figure 1 shows a high-level conceptual view of the two
models, organized into three hierarchical levels:
Fig. 1 High level conceptual view of the proposed computational model organized into three hierarchical levels
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1 the Hosts (top level),
2 the Microbiotas (middle level), and
3 the Bacterial Cells (the bottom level).
General model
The first proposedmodel is a general representation of the
most important actors involved in antibiotic resistance.
Host level (top level)
This level, whose complete model is reported in Figs. 2
and 3, describes the population of individuals in which
antibiotics resistance can spread. Figure 2 summarizes
the main functional blocks that make the model; blue
boxes represent biological sub-systems, whereas yel-
low boxes are input or observation blocks. Figure 3
shows the actual Petri-Net implementation of the Host
level.
At this level three places are dedicated to model the
possible conditions a microbiota assume with respect to
antibiotic resistance capabilities (as in Fig. 3a): (i) the
place in green refers to a condition of absence of resis-
tance, (ii) the place in yellow models a state of mild
resistance, and (iii) finally the place in red reports a state
of severe resistance. Transitions between such places rep-
resent the steps towards progressive worsening of the
antibiotic resistance state of the microbiota they are mov-
ing. At this level, each net-token represents an individual
or, more specifically, the microbiota of an individual.
Each net-token/microbiota is therefore associated to an
instance of a net class whose structure is reported in
Fig. 4. At the Host level, each token/microbiota is eval-
uated by means of its point prevalence score (PPS), that
is dynamically computed during the simulation as the
proportion of bacterial cells carrying resistance factors
over the total bacterial population [29] (Fig. 4a); the
PPS value is used at the upper network-level to take
decisions concerning whether the net-token should or
shouldn’t be moved to the next place (Fig. 3d). More
specifically, if the PPS exceeds the threshold set as the
upper bound for the current state resistance, transitions
move the microbiota net-token to the next stage of resis-
tance progression, i.e., to the next place at the host level
(Fig. 3a). In this model, PPS variations arise primarily
from antibiotic administration and microbiota preven-
tive re-integration (say, autologous transplants) events,
modeled by means of activation of administration mech-
anisms at the host and microbiota levels (Figs. 3b; 4b
and 4f). These model structures are designed to affect
both the population level, where microbiotas exist as
net-tokens (Fig. 3c presents the network structure pro-
ducing instances of them) and at the level of individual
microbiotas (Fig. 4). A backend of custom Java classes
tracks the point prevalence scores (Fig. 4d) as well as the
the number of individuals in the three different states
(Fig. 4e).
Microbiota level (median level)
Each microbiota exists at the hosts (top) level as a net-
token associated with an instance of the microbiota net-
work depicted in Figs. 5 and 4. As in the case of the
top-level, Fig. 5 reports a high-level view of the network
while Fig. 4 shows the detailed implementation.
In this more general model, at the microbiota level two
places (Fig. 4c) host tokens representing bacterial cells:
red tokens represent bacteria with antibiotic resistance
whereas green tokens represent non-resistant ones.
Resistant and non-resistant populations of bacterial
cells living into respectively the first and the second place
at the microbiota level engage into a competitive bat-
tle whose dynamics are based on the interplay between
their growth rates, availability of resources, and HGT
mechanisms. The Petri-Nets model represents each of
Fig. 2 Conceptual view of the network architecture for the hosts (top) level. Three main places describe the health states the microbiotas can
assume. The letters identify the different sections of the detailed model presented in Fig. 3
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Fig. 3 Network architecture for the hosts (top) level. Three main places describe the health states the microbiotas can assume: the non-resistant (in
green), mildly resistant (in yellow) and severely resistant (in red) states respectively (a). Transitions can move microbiota tokens, each having the
network structure from Fig. 4, to the next place. The state of non-resistance holds two microbiota tokens depicted in a compact form, i.e., with their
name only. This happens according to the value of their point prevalence score which a synchronous channel (d) reads from networks at the lower
level, possibly taking the relative microbiota to the next step along resistance progression (the structures in e track the changing numerosity of
microbiota instances in each place). Synchronous channels take care of the antibiotic administration and microbiota integration events (b),
activating network structures at the lower level (Fig. 4b and f, respectively) according to time delays and number of microbiota instances injected in
the network by the dedicated structure (c)
these mechanisms with a specific structure in the net-
work architecture: HGT mechanisms are able to turn an
existing non-resistant cell into a resistant one (Fig. 4g);
both resistant and non-resistant species contribute to the
overall population size, but through separate generative
mechanism (Fig. 4d), which in this model, for simplicity,
have the same growth rates; also the limited availabil-
ity of resources bounds the population growth (Fig. 4e).
From the Host level (Fig. 3) synchronous channels can be
dynamically activated providing new inputs to the micro-
biota simulation: antibiotic administration events cause
dose-dependent depletion of non-resistant cells (Fig. 4b)
and microbiota reintegration causes a re-population into
the state of non-resistance (Fig. 4f).
Bacterial cell level (bottom level)
In this general model, we did not implement the Bacterial
Cells as separate Petri-Nets but simply as colored tokens.
Tokens representing bacterial cells populate the two
places at the Microbiota level in Fig. 4c. They are colored
tokens, and their color is intended to carry information
about species identity and the possible presence of resis-
tance factors in the cell. They can be generated into the
microbiota by either regular population growth mecha-
nisms (Fig. 4d) or by non-resistant cells re-integration
mechanisms (Fig. 4f). Obviously, individual bacteria could
be modeled with a Petri-Net able to take into account
much more complex dynamics like for example its gene
regulatory network.
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Fig. 4 Network architecture for the microbiotas (median) level. Two main places describe two conditions each bacterial cell can assume: a state of
non-resistance (green) and a state of resistance (red), respectively (c). Horizontal transfer mechanisms can turn non-resistant cells into resistant ones
(g). Network structures managing the generation of new bacterial cells (d), total population numerosity and resources availability (e) give rise to a
competitive population dynamics between resistant and non-resistant populations. Dose-dependent depletion of non-resistant cells following
antibiotic administration (b) and microbiota reintegration (f) events activate as synchronous channels with structures in Fig. 3b. The structure in a
dynamically computes the point prevalence score of the microbiota network, making the information available for the upper level through a
synchronous channel (see Fig. 3d)
Fig. 5 Conceptual view of the network architecture for the microbiotas (median) level. Two main places describe two conditions each bacterial cell
can assume. The letters identify the different sections of the detailed model presented in Fig. 4
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Antibiotic administration and spread of resistance
(cross-layer communication)
All the three levels in the model are relevant for sys-
tem representation, as well as the capability they have for
exchanging information and affecting each other through
dedicated channels.
Such exchanges occur dynamically along simulations,
engaging the different levels in a continuous crosstalk,
connecting them through selected channels. Allowing
real-time selective communication is a requirement ful-
filled by Renew [25].
For example, antibiotic administration events take place
at the hosts (top) level (Fig. 3b) and affect all micro-
biota instances existing in the target place. In fact, the
very effects of such events affect each single microbiota
net-token, through the activation of the channel illus-
trated in Fig. 4b. Inside the single microbiota net-token,
such events cause depletion of all tokens representing
non-resistant cells, dramatically affecting the overall pop-
ulations dynamics specific to that microbiota net instance.
Another communication mechanism involves the loca-
tion of microbiota net-tokens at places reflecting their
resistance status at the top level. Each place points to a
condition: health, mild and severe resistance respectively.
Moving a microbiota instance from a state to the next
one requires the enabling and activation of the transition
between the two (Fig. 3a). This transition is enabled only
if a specific requirement is fulfilled: the PPS (dynamically
computed at the microbiota level, in Fig. 4a) must cross
the threshold corresponding to the establishment of the
next resistance stage for the microbiota, that relocates it
at the host level.
These two mechanisms involve exchanges of infor-
mation among different model levels. In the first case,
the host level imposes a way of functioning over the
microbiota level, while in the second case it takes a
decision according to information extracted from the
microbiota level.
Model tuning When dealing with multiple system levels,
as often occurs in computational system biology [21], the
model takes shape from different information and data
sources. It is necessary to carry out careful data and
model integration procedures so to leverage the available
information. The capability of NWNmodels for hybridity
allows for integrating existing models as long as consis-
tency is guaranteed. Thismust be taken into account while
choosing tuning the parameters of the model to obtain
a good trade-off between knowledge representation and
predictive capabilities.
In this context, we make a strong simplification: the
large diversity of species composing a microbiota is reca-
pitulated by tokens not carrying any information about
their species, but only indicating whether they carry resis-
tance capabilities or not. Nevertheless, the study of species
diversity and how it is affected by antibiotic treatment (for
an introduction to this problem, see [30]) is beyond the
scopes of thismodel specification (but not out of the scope
of the NWN formalism).
The proposed network architecture is based on a func-
tional description of the problem at the different levels
[31], while species identity and antibiotic or resistance
mechanisms are maintained at an abstract level. The ulti-
mate goal is to highlight some of the capabilities of a
general instrument that can be easily adapted to the pecu-
liarities of specific problems and use cases in the domain
of interest.
Acinetobacter/E.coli model
The second model we present in this paper is very
similar to the previous one at the Host level, but
it is more detailed at the Microbiota level where it
Fig. 6 Conceptual view of the network architecture for the microbiotas (median) level in the Acinetobacterium/E.coli model
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describes the dynamics of two common bacteria in the
context of antibiotic resistance. This model is based
on two experimental works treating the problem at the
level of bacterial cells [27] and at that of microbiota
hosts [28].
As introduced in the “Background” section, several
bacterial species take part to the individual microbiota.
Among them, Acinetobacterium acts as an opportunistic
pathogen, posing a real threat to immunocompromised or
injured individuals.
Besides the notoriety gained due to the threats it posed
during recent military campaigns, Acinetobacterium Bau-
manii is known to be one of themost dangerous pathogens
worldwide, having nosocomial mortality rates reaching
19-54% [26].
One of the reasons Acinetobacterium thrives in hos-
tile environments such as hospitals or battle fields, is the
capability to survive in difficult biotic and abiotic envi-
ronments by setting up a protective biofilm. This causes
the cells to stay in the environment longer, forming a
a
f
b
a
e
d
c
g
Fig. 7 Network architecture for the microbiotas (median) level in the Acinetobacterium/E.coli model. Two main places describe two conditions each
bacterial cell can assume: a state of non-resistance (green) and a state of resistance (red), respectively (c). Horizontal transfer mechanisms can turn
non-resistant cells into resistant ones (g). Network structures managing the generation of new bacterial cells, including Acinetobacterium and E.
Coli (e), total population numerosity and resources availability (d) give rise to a competitive population dynamics between resistant and
non-resistant populations. Dose-dependent depletion of non-resistant cells following antibiotic administration (b) and Bifidobacterium
reintegration (f) events activate as synchronous channels with structures in Fig. 3b. The two boxes marked with a highlight tracking structures in the
model. One dynamically computes the point prevalence score (upper box) and the other (lower box) the Acinetobacterium Resistance Level of the
microbiota network, making this information available for the upper level through synchronous channels
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Table 1 Model parameters
Model parameters Values Description
P0tot 1010 Total bacterial population
P0ByB 102 Initial Bifidobacterium population
P0AB 102 Initial Acinetobacterium population
KA 1020 Growth saturation for Acinetobacterium
KE 104 Growth saturation for E. Coli
gammaA 1.34 Growth rate for Acinetobacterium
gammaE 1.51 Growth saturation for E. Coli
Killing rate (ehnanced) 150 h-1 Frequency of predation events
HGT rate 0.15 h-1 Frequency of horizontal gene transfer
events
Quantities of bacterial cells are intended per gram of sample. Kinetic rates are
intended per hour
pathogenic reservoir, and then increasing the probability
of infection by environmental contact with other hosts.
As an additional cause for concern, this bacterial species
seems to acquire resistance to antibiotics faster compared
to many other bacterial species ([32, 33]). This causes
Acinetobacterium to reach multi drug-resistance (MDR)
rates beyond 60% ([26, 32]). As a possible explanation
for this, in [27], authors show how a particular HGT
mechanism, named bacterial predation, is able to increase
cross-species HGT events by orders of magnitude. Bac-
terial predation involves a predator species (in this case
Acinetobacterium) that, killing and destroying adjacent
prey cells, acquires their adaptive resistance genes.
In [28], the authors study the same bacterial species at
another system level: they focus on the spread and infec-
tious activity of MDR Acinetobacterium strains in the gut
Fig. 8 Results for ED1 in case of no treatment. The APPS is 48.67± 0.61 (first bar), under the threshold of mild resistance, keeping the microbiota into
the “non-resistant” state. Only in 4 cases such threshold was crossed, and the APPS for those cases is slightly higher: 57.75± 0.63 (second bar). All
cases had similar tracks, where PPS (the curve in orange) reaches a value and keeps it steadily along the simulation
Bardini et al. BMC Systems Biology 2018, 12(Suppl 6):108 Page 69 of 128
microbiota of mice, with the scope of providing an in vivo
model of post-surgery infections in hospitals. Also, they
assess how a bacterial reintegration-based therapeutical
approach is able to buffer and mitigate the rise of MDR
Acinetobacterium, reducing then the severity of the infec-
tion and improving the health conditions of the infected
host.
In this example we intend to model a system to study
how Acinetobacterium special capabilities influence the
overall resistance state of the microbiota and the preva-
lence of MDR. In this case, the three levels of the general
model are customized to represent:
• the population of murine Hosts (top level)
• the mouse gut Microbiota (middle level)
• the Bacterial Cells (bottom level)
In the following sections, we provide a more detailed
description of each level.
Population ofmurine hosts (top level)
At this level, the murine hosts receive the treatments indi-
cated in the experimental design, i.e., antibiotic treatment
possibly in combination with microbial reintegration.
A dedicated network structure simulates the antibiotic
administration (with the correct dosage and administra-
tion frequency) that is propagated to each net-token,
which represents an individual microbiota. As in the
Fig. 9 Results for ED1 in case of traditional treatment in which two doses of antibiotic were administered to the microbiota, the first lower and the
second higher. The APPSs for the three significant stages of the experiment are: 50.34± 0.88 before treatment (homologous to that in Fig. 8),
64.74± 1.14 after the first dose (beyond the threshold for mild resistance) and 93.24± 2.4 after the higher dose, beyond the threshold for severe
resistance. The simulation track of the PPS shows that after each dose (the curve in blue, whose peaks represent doses administration) PPS increases
proportionally, moving from the “non-resistant” steady state, to the “mildly resistant” one, and finally to the “severely resistant” state, where it stays
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previous model, each net-token can move among three
possible places (no/mild/severe resistance) depending on
its PPS score.
Murine gutmicrobiota (middle level)
At this level we create a simplified model of the diver-
sity inherent to the microbiota. Figure 6 shows its
high-level structure while Fig. 7 reports its detailed
implementation.
Different bacterial species compete for the ecological
space in the gut niche. Development of MDR in Acineto-
bacterium cells emerges from standard HGTmechanisms
(Fig. 7g) and from bacterial predation (Fig. 7b); both
mechanisms are implemented with a dedicated structure.
Predation can occur at variable rates [27].
Other bacterial species, from the point of view of Acine-
tobacterium studies, function also as preys and, possibly,
as source of acquirable resistance factors.
At this level antibiotic resistance of the microbiota is
quantified by its PPS score, and by the Acinetobacterium
Resistance Level (ARL). The ARL is computed as the
average amount of antibiotic resistant DNA factors
acquired through bacterial predation divided by the num-
ber of total predation events. This score can be used
to quantify the probability of a population to acquire
multi-drug resistance factors.
Fig. 10 Results for ED1 in case of innovative protocol. We observe how this protocol lowers APPS both in the second and in the third stages of the
experiment: while pretreatment APPS remains homologous to those in Figs. 8 and 9 (50.94± 0.67), after the first dose of antibiotic and microbiota
reintegration it drops to 53.03± 0.52. Eventually, after the second dose of antibiotics it reaches 70.75± 0.82, corresponding to significant decreases
compared to the corresponding simulation stages in the traditional treatment scenario Fig. 9. In the simulation curve, we observe how the effects of
the first antibiotic dose on PPS are counterbalanced by the microbiota reintegration: in the first place PPS begins to rise, but it is bounded right
away to a low level by the preventive action, leaving on the track just a transient spike. After the second, higher dosage of antibiotics, PPS increases,
reaching a steady state at a higher level, which is anyway lower that that reached in Fig. 9
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Bacterial cells (bottom level)
Also in this second model bacterial cells are coded
as colored tokens moving in the Microbiota level net-
work. The color identifies the species (Acinetobacterium,
E.Coli, Bifidobacterium, and generic commensal bacte-
ria), and their antibiotic resistance level. Only tokens
marked as Acinetobacterium can cumulate resistance fac-
tors through bacterial predation. In addition, an explicit
modeling of time is provided to accurately integrate
kinetic constants from [27] into the model. This allows
us to compare the simulation outcomes with the exper-
imental results, and to explicitly define timings for
treatment administration or for emergence of particu-
lar environmental conditions relevant to the simulation
(e.g., relative population densities favoring or not bacterial
predation).
Parameter identification
The mechanism of bacterial predation involving Acine-
tobacterium and E.Coli is parametrized following [27] by
adapting their mathematical descriptions to the network
structures of this model. The most important parame-
ters are reported in Table 1. Each simulation is initialized
to reproduce the initial conditions presented in [28] to
depict the untreated individuals. Quantitative information
in the model refers to a single gram of microbiota. Killing
enhancement described in [27] can reach a factor of 3 if
the conditions in terms of relative population densities
Fig. 11 Results for ED2 in case of traditional treatment in which a single high dose of antibiotic is administered to the microbiota. The administration
of a single high dose of antibiotics was presented to each microbiota instance. This corresponded to an average onset time for severe resistance
(AT) of 162.87± 7.78. Simulation tracks from these experiments show healthy individuals (blue curve) progressively acquiring resistance. Some of
them reach severe resistance right away (yellow curve), while most of them pass through a phase of mild resistance (orange curve)
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between predator and prey are optimal. In our model we
set initial conditions so that the population sizes of Acine-
tobacterium and E.Coli favor the presence of the killing
enhancement phenomenon.
Results and discussion
To showcase the potential of multi-level and hybrid
models for studying antibiotic resistance progression,
we present three experimental designs for analyzing the
problem focusing on different abstraction levels.
The first two experimental designs (ED1 and ED2) are
based on the General Model. One experiment aims at
evaluating how standard antibiotic treatments can cause
and speed up the spread of resistance factors in a single
microbiota. The second experiment is instead centered at
the population level: multiple instances of the microbiota
net are generated at the top level to represent a population
of hosts distributed into the three defined resistance states
and their dynamics is simulated. The third experimental
design (ED3), executed on the Acinetobacterium/E.Coli
Model, focuses on the effect of antibiotic treatments on
the resistance level of a murine microbiota infected with
Acinetobacterium.
In each experiment, the initial setting of the simulation
represents hosts that did not receive any treatment admin-
istration, where the non-resistant bacterial population
prevails largely over the resistant one.
Given the observed variance across simulations, we
chose a number of 30 simulation runs per experimental
condition, which guarantees a 5% error margin at a 95%
confidence interval under all experimental designs.
Experimental design ED1
In the first experimental design ED1, three different
experimental conditions are considered:
• no antibiotic treatment (Fig. 8);
• two administration events: a low dose followed by a
second higher dose (Fig. 9);
• an innovative treatment protocol, where in parallel to
the first low antibiotic dose, we simulate
reintegration of non-resistant bacterial cells in the
Fig. 12 Results for ED2 in case of innovative treatment in which a single high dose of antibiotic combined with bacterial reintegration is
administered to the microbiota. Microbiota reintegration combined with antibiotic administration yields an increased AT (178.64± 7.4) with respect
to that observed with the administration of the antibiotics alone Fig. 11. In simulation tracks we notice how the overall migration of healthy
individuals towards a worsening resistant state slows down, resulting in a slower severe resistance onset time (T)
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microbiota (Fig. 10). This reinforces the non-resistant
population by mitigating the advantage acquired by
the resistant cells after the antibiotic administration
in the competition for colonizing the gut niche. This
design is inspired by existing clinical practices such as
autologous microbiota transplants, also called
bacterial therapy [12].
In this first experimental design, simulations track the
PPS of a single microbiota; this measure is correlated with
the presence of resistant cells within the total bacterial
population. PPS score is sampled at different stages of the
simulation:
• before the administration of any treatment;
• after the administration of the first, low dose of
antibiotic (plus, for the innovative protocol, the
microbiota integration)
• after the administration of the second higher dose of
antibiotics.
The values presented in Figs. 8, 9, 10 are computed as
the average point prevalence score (APPS) over 30 sim-
ulation runs. Each simulation is slightly different thanks
to the stochasticity introduced in the model. This type of
simulation allows us to study, given the internal popula-
tion dynamics of resistant and non-resistant species, the
link between the overall resistance state of a microbiota
and the different treatment protocols.
In the first experimental condition, when no treatment
is provided, the APPS remains at a low and almost con-
stant level during the whole simulation. Small increases
are caused by the activation of random mutations and/or
horizontal gene transfer events. In only 4 out of 30
experiments the score exceeded the threshold required
to assign the microbiota into a state of mild resistance.
Fig. 13 Results of PPS tracking for ED3 in case of no treatment administration to the murine microbiotas. When no treatment was administered to
murine hosts, AP is 2.27 ± 0.04 at day 0, 25.3± 0.07 at day 7 and reaches 72.29± 0.07 at the end of the experiment, at day 14. Simulation tracks show
PPS increasing steadily and slowly compared to Fig. 14)
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The relative averaged APPS of 57.75± 0.63 (second bar
of Fig. 8) refers to these four cases. All remaining sim-
ulations are represented by the first bar of Fig. 8, show-
ing that the microbiota remained in an healthy state,
with an APPS score of 48.67± 0.61. In none of the
simulations the microbiota reached a state of severe
resistance.
In the second experimental condition, the model simu-
lates a treatment protocol composed of two administra-
tions of an increasing dose of antibiotic (Fig. 9). Before
treatment (as in the control condition), the APPS was
50.34± 0.88. The administration of the first lower dose
allows a partial recovery of the non-resistant portion of
the bacterial population (APPS of 64.74± 1.14); the sec-
ond higher dose, instead, takes the microbiota towards a
state of increased resistance (APPS 93.24± 2.4).
In the third experimental condition (Fig. 10), the pre-
vious treatment protocol is improved with a parallel
preventive reintegration of non resistant bacterial cells;
this improved protocol has a significant effect after each
antibiotic dose: the APPS decreases of 18.08% after the
first dose (when compared to that originating from the
traditional treatment alone), and decreases of 24.12%w.r.t.
the traditional protocol after the second antibiotic dose.
If we look at the PPS during the whole simulation,
it is evident how it is constant when no treatment is
administered (Fig. 8). With a traditional treatment, it
increases in correspondence with the administration of
the two antibiotic doses (blue curve in Fig. 9). The same
dynamic can be observed in Fig. 10, with the differ-
ence that the preventive action of bacterial reintegra-
tion mitigates the resistance effects of the first dose of
antibiotics, taking the PPS score to a level similar to
pre-treatment.
Experimental design ED2
The second experimental design ED2 focuses on the host
population level; we created multiple instances of the
Fig. 14 Results of PPS tracking for ED3 in case of daily administration of antibiotic treatment to the murine microbiotas. Simulating daily
administration of antibiotic doses to the mice we observe, for the three relevant time points of the experiment, an AP of 2.5± 0.05 (day 0), very close
to the result in Fig. 13; after seven days of daily antibiotic administration, AP is 37.57± 1.04 (day 7), and after seven days more reaches the value of
359.21± 30.11 (day 14). The simulation curve shows how PPS grows faster compared to Fig. 13, reflecting the movement of population dynamics
towards the establishment of the domination of the microbiota by resistant species
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microbiota net-token in order to represent a population
of hosts. In this second experiment, we simulated the
following experimental conditions:
• in the control condition no treatment is administered;
• a single, high-dosage administration event takes place
(Fig. 11);
• a preventive bacterial reintegration occurs in parallel
to the single high-dosage antibiotic administration
(Fig. 12).
We simulated 50 instances of the microbiota network.
As a metric to analyze the evolution of the population we
consider the simulation time at which the number of hosts
in a state of severe resistance exceeds the number of hosts
in a state of mild resistance (that we define as the severe
resistance onset time, T); this represents a landmark of the
process degeneration towards extensive resistance spread
and diffusion.
When no treatment is administered, microbiotas do
not get to a state of severe resistance. Instead, as
we can observe in Fig. 11, with a single high-dosage
administration of antibiotic alone, the onset of a state
of prevalent severe resistance within the hosts popu-
lation is observed at an average onset time (AT) of
162.87± 7.78. When microbiota re-integration is pro-
vided in parallel with the antibiotic dose, there is an
average delay of 9.68% in AT, 178.64± 7.4, see Fig. 12.
Examples of the typical temporal dynamics in the two
Fig. 15 Results of PPS tracking for ED3 in case of daily administration of antibiotic treatment combined with Bifidobacterium reintegration to the
murine microbiotas. The combination of antibiotic administration and bacterial reintegration lowers AP values both at day 7 and 14. While AP at day
0 has a value of 2.54± 0.04, similar to those reported in Figs. 13 and 14, after seven days of combined treatment daily administration AP is
35.25± 0.51, and at day 14 reaches the value of 235.94± 7.9. This assesses the mitigating action by bacterial reintegration over the resistance levels
observed when simulating the administration of antibiotic treatment alone Fig. 14. Simulation tracks show how PPS grows in time at a pace slower
than that observed in case of antibiotic treatment alone(Fig. 13)
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experimental conditions are provided respectively in
Figs. 11 and 12.
Experimental design ED3
In this last experimental design, we compare the behavior
of an untreated microbiota, another one receiving antibi-
otic treatment, and finally a third one receiving antibi-
otic treatment combined with bacterial reintegration. The
objective is to observe the spread of resistance levels in the
Acinetobacteria and overall microbiota population.
The experiments are organized on the following time-
line:
• at day 0 (in [28], day -7) daily administration begins
and it goes on until day 14.
• at day 7 (in [28], day 0: infection with MDR
Acinetobacterium relative bacterial population
densities arise so to cause a killing enhancement of a
factor of 2 in Acinetobacteria, corresponding to
increasing the probability that they acquire MDR.
• at day 14 the experiment is interrupted, and the
variables of interest assessed.
Simulation of treatment includes antibiotic administra-
tion and, possibly, bacterial reintegration with Bifidobac-
terium Fig. 7f.
Simulations cover the time period of 14 days, and
time is explicitly modeled and simulated. To assess how
the different modelled mechanisms affect the spread of
antibiotic resistance, we track both PPS scores and, only
for Acinetobacteria, ARL scores at the end of the first, the
seventh, and the fourteenth days in the simulation time-
line. Time intervals replicate those from the experimental
design of [28].
In Figs. 13, 14, 15, 16, 17, and 18 we separately present
results for PPS and ARL tracking respectively.
Antibiotic administration causes average PPS to
increase significantly, especially at day 14: while in
the first experimental condition (no treatment) APPS
is 72.29± 0.07 (Fig. 13), in the simulations including
antibiotic treatment it reaches the value of 359.21± 30.11
Fig. 14. In Fig. 15 we observe how the combination of
antibiotic administration and bacterial reintegration low-
ers the score both at day 7 and 14 compared to the case
where antibiotics alone were administered; after seven
Fig. 16 Results of ARL tracking for ED3 in case of no treatment administration to the murine microbiotas. When simulating a condition of absence of
treatment, average ARL (AARL) assumes values of 4.83± 0.12 at day 0, 7.6± 0.19 at day 7 and 10.33± 0.18 at the end of the experiment, at day 14.
Simulation tracks show a slow and steady increase of ARL along simulation time
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Fig. 17 Results of ARL tracking for ED3 in case of daily administration of antibiotic treatment to the murine microbiotas. Simulation of daily
antibiotics administration to the murine microbiotas yields to AARL values of 5.12± 0.2 at day 0, 7.77± 0.23 at day 7 and 10.61± 0.22 at day 14.
Similarly to Fig. 16, simulation tracks show a slow and steady increase of ARL along simulation time
days of the combined treatment APPS is 35.25± 0.51, and
at day 14 it reaches the value of 235.94± 7.9.
As it can be observed, average ARL (AARL) tends
to increase along simulation time, reflecting the grow-
ing pool of DNA exchanged through predation by
Acinetobacterium. No significant variations are observed
across experimental conditions (Figs. 16, 17, 18), report-
ing that the MDR level in Acinetobacteria grows steadily
during the time of the experiments, as exemplified by the
simulation tracks.
These results considered together are coherent with
those presented in [28], where the effect of bacterial rein-
tegration is measured evaluating the spread of resistant
Acinetobacterium infection in the host during antibi-
otic treatment. They show reductions of the Acineto-
bacterium infection spread when bacterial reintegration
combines with antibiotic treatment compared with the
case antibiotic treatment is administered alone. Consid-
ering that as an indirect measure for the resistance level
in Acinetobacteria, our results, indicating a 30% reduc-
tion of resistance level in the whole microbiota in case of
bacterial reintegration, assess the capability of our model
for making consistent predictions.
Even though antibiotic treatment and bacterial
reintegration do not seem to affect the propensity of
Acinetobacterium towards acquiring exogenous, poten-
tially resistant DNA (as shown in Figs. 16, 17, 18), they
do affect the overall resistance level of the microbiota,
and thus the probability a predation event leading to the
acquirement of multi-drug resistance.
Conclusions
In this work, we suggest some potential applications
of NWN models for investigating the relations between
antibiotic treatment and the spread of antibiotic resistance
within a microbiota, and across hosts populations. The
use of a multi-level and hybrid formalism allows integrat-
ing different types of data, as well as to describe the system
under study at multiple levels: in the context of antibiotic
resistance, they allow modeling the system from the level
of bacterial cells and resistance-carrying molecules, to the
microbiota they are part of, up to the population of hosts
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Fig. 18 Results of ARL tracking for ED3 in case of daily administration of antibiotic treatment combined with Bifidobacterium reintegration to the
murine microbiotas. Combining Bifidobacterium reintegration to antibiotic doses in daily treatment administration AARL is 4.93± 0.14 at day 0,
7.46± 0.16 at day 7, and 10.13± 0.15 at day 14, and simulation tracks show a slow and steady increase of ARL along simulation time, similarly to what
it is observed both in case of no treatment administration (Fig. 16) and of daily antibiotic administration alone (Fig. 17)
undergoing different treatments and interacting between
each other. Simulations enable to take into account the
timing and stochastic behaviors required to model admin-
istration protocols as well as the stochasticity intrinsic to
biological processes.
In this work we want to underline how models of this
kind not only provide valuable tools for investigating
causal, quantitative relations between different events and
mechanisms, but can be used as supports for decision
making processes and clinical protocols development.
The presented models, in their current form, present
strong simplifications. Nevertheless, their flexibility
makes it easy to adapt them to specific and more realistic
and detailed use cases, built gathering realistic data from
the field.
Our future work includes applying the presented
modeling strategy to first-hand data. This will be the
first step towards the combination of hypothesis-driven
model specification with data-driven parameter iden-
tification. This combination, along with the consis-
tent model and information integration processes, will
allow to extract new knowledge, to guide new experi-
ments, and to generate new data from the systems of
interest.
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